ProKidney to Showcase Innovations at UBS Virtual Organ Restoration Day
ProKidney Corp. (Nasdaq: PROK), a trailblazer in biotechnology focusing on combating chronic kidney disease (CKD), is set to participate actively in the upcoming UBS Virtual Organ Restoration Day. This important event is scheduled for October 15, 2024, and will feature key management personnel from ProKidney that are eager to share insights into their groundbreaking therapies.
Event Details and Participation
The UBS Virtual Organ Restoration Day is an exceptional platform for discussing advancements in organ restoration and therapies related to chronic illnesses. ProKidney's participation aims to highlight their unique approach to treating CKD through innovative cellular therapies, showcasing their commitment to improving patient outcomes.
Key Event Information
The fireside chat will take place on Tuesday, October 15, 2024, at 9:00 AM ET. This format will allow for a robust dialogue on the latest in biotechnology, with ProKidney exhibiting their lead product candidate, rilparencel. Interested parties can listen to this informative session live.
Accessing the Live Stream
The live webcast will be hosted on ProKidney's official website under the ‘Events’ section. Following the discussion, a recording will be available to stream for 90 days, ensuring wider accessibility for those unable to attend in real-time.
One-on-One Meetings for Investors
In addition to the fireside chat, ProKidney is offering personalized meetings for interested investors during the event. This initiative aims to deepen investor understanding and foster meaningful discussions regarding the company's cutting-edge research and development strategies. Investors are encouraged to coordinate with their UBS representatives for scheduling opportunities.
About ProKidney Corp.
Founded in 2015, ProKidney is pioneering advancements in cellular therapy to address the challenges posed by chronic kidney disease. After a decade of meticulous research, the company’s flagship product, rilparencel, is undergoing trials in Phase 2 and Phase 3 studies, aiming to preserve kidney functionality among diabetic patients at risk of renal failure. Notably, rilparencel has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, underlining its significant potential in transforming CKD treatment.
Contact Information for Investors
ProKidney encourages investor inquiries and offers various communication channels to facilitate discussions:
ProKidney
Ethan Holdaway
Email: Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Email: Daniel@lifesciadvisors.com
Frequently Asked Questions
What is ProKidney Corp. known for?
ProKidney is recognized for developing innovative therapies for chronic kidney disease, particularly focusing on cellular therapy.
When is the UBS Virtual Organ Restoration Day?
The event is scheduled for October 15, 2024, at 9:00 AM ET.
How can investors participate in the event?
Investors can join the fireside chat live through ProKidney's official website and schedule one-on-one meetings through their UBS representatives.
What is rilparencel?
Rilparencel is ProKidney's leading therapy candidate aimed at preserving kidney function in patients at high risk of renal failure.
What designation has rilparencel received from the FDA?
Rilparencel has been granted Regenerative Medicine Advanced Therapy (RMAT) designation, highlighting its potential as a vital treatment option.